Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCYZ7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc. for Xolair 150 mg/ml autoinjector on December 5, 2025, with an ultimate completion date of December 29, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order will be fulfilled at the company's Park Ridge location and represents one of numerous purchase orders DMS Pharmaceutical Group has received from the DLA Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The prime IDC, awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The parent contract authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. No subcontractors have been identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FCYZ7?
SPE2DR26FCYZ7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FCYZ7 worth?
The government has obligated $10,485 on SPE2DR26FCYZ7.
Is contract SPE2DR26FCYZ7 an order under another contract?
Yes. SPE2DR26FCYZ7 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYZ7 competed?
The extent of competition for SPE2DR26FCYZ7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award